Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shares Acquired by Brevan Howard Capital Management LP

Brevan Howard Capital Management LP raised its stake in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 232.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 34,556 shares of the biotechnology company's stock after buying an additional 24,153 shares during the quarter. Brevan Howard Capital Management LP's holdings in Arrowhead Pharmaceuticals were worth $650,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Captrust Financial Advisors lifted its position in shares of Arrowhead Pharmaceuticals by 13.5% during the fourth quarter. Captrust Financial Advisors now owns 17,074 shares of the biotechnology company's stock worth $321,000 after purchasing an additional 2,035 shares during the last quarter. Balyasny Asset Management L.P. lifted its position in shares of Arrowhead Pharmaceuticals by 266.0% during the fourth quarter. Balyasny Asset Management L.P. now owns 372,749 shares of the biotechnology company's stock worth $7,008,000 after purchasing an additional 270,897 shares during the last quarter. BNP Paribas Financial Markets lifted its position in shares of Arrowhead Pharmaceuticals by 59.5% during the fourth quarter. BNP Paribas Financial Markets now owns 88,029 shares of the biotechnology company's stock worth $1,655,000 after purchasing an additional 32,841 shares during the last quarter. Ameriprise Financial Inc. lifted its position in shares of Arrowhead Pharmaceuticals by 2.6% during the fourth quarter. Ameriprise Financial Inc. now owns 224,988 shares of the biotechnology company's stock worth $4,230,000 after purchasing an additional 5,732 shares during the last quarter. Finally, Schonfeld Strategic Advisors LLC lifted its position in shares of Arrowhead Pharmaceuticals by 63.1% during the fourth quarter. Schonfeld Strategic Advisors LLC now owns 632,214 shares of the biotechnology company's stock worth $11,886,000 after purchasing an additional 244,527 shares during the last quarter. 62.61% of the stock is currently owned by institutional investors.

Insider Transactions at Arrowhead Pharmaceuticals

In other news, CEO Christopher Richard Anzalone sold 50,800 shares of the stock in a transaction that occurred on Friday, April 11th. The stock was sold at an average price of $11.49, for a total transaction of $583,692.00. Following the transaction, the chief executive officer now owns 3,921,255 shares in the company, valued at $45,055,219.95. This trade represents a 1.28% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders have sold a total of 275,880 shares of company stock valued at $4,034,037 in the last ninety days. 4.30% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several research firms have recently weighed in on ARWR. Chardan Capital reiterated a "buy" rating and set a $60.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Tuesday. Royal Bank of Canada reiterated an "outperform" rating and set a $42.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, February 11th. B. Riley restated a "buy" rating and set a $38.00 price target (down previously from $51.00) on shares of Arrowhead Pharmaceuticals in a research note on Friday, February 14th. HC Wainwright restated a "buy" rating and set a $80.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, February 12th. Finally, Citigroup cut their price target on Arrowhead Pharmaceuticals from $21.00 to $17.00 and set a "neutral" rating on the stock in a research note on Tuesday. One research analyst has rated the stock with a sell rating, three have given a hold rating and six have given a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $42.13.

Arrowhead Pharmaceuticals Stock Performance

Arrowhead Pharmaceuticals stock traded down $0.04 during mid-day trading on Wednesday, hitting $15.24. The company had a trading volume of 1,126,781 shares, compared to its average volume of 1,470,936. The company has a current ratio of 6.09, a quick ratio of 6.09 and a debt-to-equity ratio of 7.27. Arrowhead Pharmaceuticals, Inc. has a 12-month low of $9.57 and a 12-month high of $30.41. The company's fifty day moving average is $13.33 and its 200-day moving average is $17.89. The company has a market capitalization of $2.09 billion, a price-to-earnings ratio of -2.95 and a beta of 0.89.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last released its quarterly earnings data on Monday, May 12th. The biotechnology company reported $2.75 EPS for the quarter, topping the consensus estimate of ($0.06) by $2.81. The company had revenue of $542.71 million during the quarter, compared to analysts' expectations of $116.27 million. During the same quarter in the prior year, the company posted ($1.02) EPS. Equities research analysts predict that Arrowhead Pharmaceuticals, Inc. will post -2.42 EPS for the current year.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.